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Abstract 
Short communication on on t(10;17)(p15;q21) 
ZMYND11/MBTD1, with data on clinics, and the 
genes implicated. 
Clinics and pathology 
Disease 
Acute myeloid leukemia (AML), poorly 
differentiated, AML without maturation or with 
minimal maturation (AML-M0, and AML-M1) 
Epidemiology 
This is a rare chromosomal rearrangement, only 
reported in four cases of AML without or with 
minimal maturation, without molecular 
characterization (Pollak and Hagemeijer, 1987; 
Shah et al., 2001; Barjesteh van Waalwijk et al., 
2003; Dicker et al., 2007).  
We add two cases with molecular cytogenetic 
studies (Tempescul et al., 2007; De Braekeleer et 
al., 2014).There were 2 cases of AML-M0 and 4 
cases of AML-M1. 
Clinics 
Patients were aged 11, 13, 16 and 40 years. There 
were 3 male and 3 female patients. 
Treatment 
Treatments of the patients reported in Tempescul et 
al. 2007, De Braekeleer et al. 2014 were the 
following: (P1) induction therapy followed by three 
consolidation courses leading to complete 
remission; (P2) induction therapy followed by  
consolidation therapy leading to complete 
remission, then relapse and second complete 
remission, then bone marrow transplantation. 
Evolution 
(P1) alive in complete remission 71 months 
following diagnosis; (P2) died 37 months following 
the initial diagnosis. Another patient reported in the 
literature was in complete remission at 42 months 
after diagnosis. 
Cytogenetics 
Note 
The t(10;17)(p15;q21) involves two genes that were 
not previously reported to form a putative fusion 
gene. 
Cytogenetics morphological 
t(10;17)(p15;q21) is identified by banding 
cytogenetics. 
Cytogenetics molecular 
To determine the position of the breakpoints on 
chromosomes 10 and 17, BACs located in the 
bands of interest were used as probes in FISH 
experiments. Analysis with RP11-387K19 showed 
that one signal hybridized to the normal 
chromosome 10, and the other split and hybridized 
to both der(10) and der(17). Analysis with RP11-
326B24 showed that one signal hybridized to the 
normal chromosome 17, and the other split and 
hybridized to both der(17) and der(10). Co-
hybridization with both BAC clones showed two 
fusion signals. RP11-387K19 contains the 
ZMYND11 gene and RP11-326B24 the MBTD1 
gene. 
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FISH with BACs RP11-387K19 (spectrum orange, located in 10p15 and containing ZMYND11) and RP11-326B24 (spectrum 
green, located in 17q21 and containing MBTD1) showing co-hybridization. 
 
Genes involved and 
proteins 
ZMYND11 
Location 
10p15.3 (according to UCSC Genome Browser on 
Human Feb. 2009 (GRCh37/hg19) Assembly) 
DNA/RNA 
The ZMYND11 gene contains 15 exons, of which 
14 are coding, spanning 120 kb. Different isoforms 
are generated by seven alternatively spliced 
transcript variants (Hateboer et al., 1995). 
Protein 
The protein localizes to the nucleus and contains 3 
motifs involved in transcription regulation: a PHD 
finger and bromodomain in its N-terminal half, and 
a MYND domain (conserved 2-zinc finger motif) at 
its C terminus. The MYND domain interacts with 
the N-CoR/mSin3/HDAC1 complex that causes 
transcriptional repression (Masselink and Bernards, 
2000). 
MBTD1 
Location 
17q21.33 
DNA/RNA 
The MBTD1 gene contains 17 exons, of which 15 
are coding, spanning 82 kb. Seven transcript 
variants are known (Eryilmaz et al., 2009). 
Protein 
MBTD1 localizes to the nucleus and contains a 
FCS-type zinc finger at the N-terminus with 
putative regulatory function and four MBT 
(malignant brain tumor) repeats at the C-terminus. 
MBTD1 is a putative Polycomb group protein, 
which are known to maintain the transcriptionally 
repressive state of genes, probably via chromatin 
remodeling (Nady et al., 2012). 
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